Search Results
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder
More news about: Johnson & Johnson
Dec 03, 2025, 12:59 ET U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
doses. This trial's primary endpoint is progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, as assessed by blinded independent review committee (IRC). Secondary endpoints include PFS, as assessed by investigator; overall response rate (ORR) and
More news about: Eli Lilly and Company
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
approved dosing of glofitamab). Primary endpoints of the study include safety and tolerability. Secondary efficacy endpoints include ORR, DOR, CRR, PFS, RFS, and OS as well as pharmacokinetics and immunogenicity.For more information about the LOTIS-7 trial, visit
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
plus tislelizumab and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. Ziihera plus tislelizumab and chemotherapy also demonstrated clinically meaningful
More news about: Jazz Pharmaceuticals plc
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
combination with R2 for patients with relapsed or refractory (R/R) FL (n=243) demonstrate significantly superior progression-free survival (PFS) and overall response rates (ORR) compared to standard of care R2 (n=245).1The study showed that treatment with epcoritamab
More news about: AbbVie Inc.
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
disease management & wearable injectorsRising contamination concerns encouraging pharma to shift toward closed-system PFSStrong governmental demand for PFS-based vaccination programsAutomation & robotics in fill–finish enabling scale expansion and cost competitivenessTechnology
More news about: Vantage Market Research
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
such as FOLFOX (5-FU/LV/oxaliplatin) and FOLFIRI (5-FU/LV/irinotecan), yield higher response rates, improved progression-free survival (PFS), and better overall outcomes compared to 5-FU/LV alone. For patients who no longer respond to FOLFOX or CAPEOX, second-line therapy typically involves
More news about: DelveInsight Business Research, LLP
Dec 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and
More news about: ADC Therapeutics SA
Dec 01, 2025, 06:30 ET Denison & Ya'thi Néné Lands and Resources Announce Signing of the Nuhenéné Benefit Agreement with Three First Nations and Four Municipalities
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Dec 01, 2025, 06:00 ET Thesis Gold Announces Positive Prefeasibility Study for Lawyers-Ranch Project: After-Tax NPV5% of $2.37 Billion and 54.4% IRR
announce positive results from an independent Prefeasibility Study ("PFS") for its 100% owned Lawyers-Ranch Project ("Lawyers-Ranch" or the "Project") in the prolific Toodoggone Mining District of British Columbia.The PFS was prepared by Ausenco Engineering Canada ULC. ("Ausenco"), Mining
More news about: Thesis Gold Inc.
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
and the disease control rate was 71%. Median DOR was not reached, and the 12-month probability of sustained response was 53%. Median PFS was 5.5 months, with 12-month PFS rate was 29%. Safety with sac-TMT was manageable, the most frequent grade 3 or 4 treatment-related adverse events (AEs) (≥5%) were hematologic
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 26, 2025, 07:00 ET Blue Sky Uranium Completes Comprehensive GAP Analysis for Ivana Deposit and Identifies Clear Roadmap to Feasibility
updateQ2 2026: Preliminary metallurgical results and commencement of extended metallurgical testsQ3 2026: PFS level of engineeringQ3 2026: Final mineral resource report and PFS completionQ2 2027: Final Metallurgical test report and FS completionQ3 2027: EIA submissionThe
More news about: Blue Sky Uranium Corp.
Nov 25, 2025, 07:30 ET Medicare Finalizes Reimbursement for Caristo's CaRi-Plaque™ Across Hospital and Office Settings
New OPPS and PFS reimbursement rates give hospitals, imaging centers and physicians a unified path to use AI plaque analysis starting 2026STAMFORD, Conn., Nov. 25, 2025 /PRNewswire/ --
More news about: CARISTO DIAGNOSTICS
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
metastatic breast cancer. The presentation will feature a pre-specified interim overall survival (OS) analysis, with updates on progression-free survival (PFS) and time to chemotherapy (TTC). In addition, a poster presentation will provide results of an exploratory analysis of early changes in circulating tumor
More news about: Eli Lilly and Company
Nov 24, 2025, 08:30 ET Amorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer Patients
Center and the Israel Ministry of Health, aims to investigate whether this therapy can extend the survival of these patients by time to progression (PFS), overall survival (OS), response rate (ORR), and change in quality of life using a dedicated questionnaire. Data is expected in Q3 of 2026.Pancreatic
More news about: Amorphical
Nov 24, 2025, 07:30 ET Defense Metals Receives Support from the McLeod Lake Indian Band while Meeting in Ottawa with Canadian Government Officials to Advance the Wicheeda Rare Earth Project
hydroelectric transmission lines, gas pipelines, rail services and the port facilities at Prince Rupert. The Company completed a Preliminary Feasibility Study (PFS) in 2025 (refer to the Company's news releases dated February 18, and April 7, 2025).For further information, please visit
More news about: Defense Metals Corp.
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
second-line and later settings and has achieved dual benefits in PFS and overall survival (OS) in the EGFR-TKI-resistant lung cancer population, making it the first ADC to show statistically significant and clinically meaningful improvements in both PFS and OS compared to platinum doublet chemotherapy. These
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 24, 2025, 07:00 ET Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
cycles over approximately 10 months before disease progression occurred.The extended Progression Free Survival (PFS) of each of these patients is consistent with long-term PFS seen in several patients in prior early-stage clinical trials of REQORSA and is not expected with treatment with osimertinib
More news about: Genprex, Inc.
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
and standard chemotherapy (gemcitabine and nab-paclitaxel).A prespecified interim analysis is planned when 40% of progression-free survival (PFS) events are observed.Sickle Cell Disease (SCD) & Gene TherapyAnnounced that a poster featuring final
More news about: BioLineRx Ltd.
Nov 20, 2025, 07:58 ET ARIS MINING TO ACQUIRE REMAINING 49% OF SOTO NORTE, SECURING 100% OWNERSHIP AND ADVANCING A CLEAR PATH TO 1 Moz/year
and Marmato in Colombia and the near-term advancement of Toroparu in Guyana, which is expected to be construction-ready following completion of the PFS next year. Full alignment and strategic control: 100% ownership enhances Aris Mining's ability
More news about: Aris Mining Corporation
Nov 19, 2025, 17:00 ET ARIS MINING AND THE GOVERNMENT OF COLOMBIA REACH LONG-TERM AGREEMENT FOCUSED ON SECURITY AND SUSTAINABILITY TO END ICSID ARBITRATION
gold project, where a new Preliminary Economic Assessment has been completed and a Prefeasibility Study is in progress. Following completion of the PFS, Toroparu will be positioned to advance toward construction. Aris Mining also holds a 51% interest in the Soto Norte joint venture,
More news about: Aris Mining Corporation
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
Japan).3,4 The primary outcome measure of the trial is OS.3 Key secondary outcome measures include progression-free survival (PFS) and patient-reported outcomes (PROs) including disease-related symptoms, physical function, and quality of life.3 Results from DeLLphi-304
More news about: Amgen
Nov 19, 2025, 08:46 ET CMS Establishes National Pricing for Vesiflo's inFlow™ Voiding Prosthesis
CPT® codes related to physician procedures for the device. This decision, included in the Calendar Year 2026 Medicare Physician Fee Schedule (PFS) Final Rule (CMS-1832-F), will take effect January 1, 2026, ensuring consistent nationwide coverage for physicians treating women with permanent urinary
More news about: Vesiflo
Nov 18, 2025, 12:47 ET AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
compared to 74% of patients treated with R2 (n=181/245, 95% CI: 68%-79%). The median for dual primary endpoint of progression-free survival (PFS), was not reached (NR) among patients treated with EPKINLY + R2 (95% CI: 21.9 months - NR) compared to 11.2 months for patients treated with
More news about: AbbVie